Gateway 2012: Veltek Associates, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: Veltek Associates, Inc.


Veltek Associates, Inc.
Company Profile

Veltek Associates, Inc. (VAI) is an EPA and FDA registered manufacturing facility. We focus on identification and control of contamination in classified areas. We produce a complete range of sterile pharmaceutical grade disinfectants, sporicides, lubricants, and buffer solutions; Asepti-Cleanse sterile IPA/ hand sanitizer hands-free dispensers; Environmental Monitoring Systems; Core2Clean Spray/Mop/Fog Systems.

The patented SimpleMIX® System is designed for the mixing of sterile disinfectants/sporicides in a sealed multi-chamber container eliminating concerns over handling and improper mixing of chemicals. Just push the internal cap and the two solutions instantly mix together. Visit us at InterPhex booth # 2508 to see all VAI’s product offerings.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here